74627-27-3

Basic information

• Product Name: (5R,8R,10R)-2-chloro-6-methyl-8-ergolinylmethyl p-toluenesulfonate
• CAS NO: 74627-27-3
• Molecular Weight: 444.982
• Mol File: 74627-27-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (5R,8R,10R)-2-chloro-6-methyl-8-ergolinylmethyl p-toluenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: (5R,8R,10R)-2-chloro-6-methyl-8-ergolinylmethyl p-toluenesulfonate(74627-27-3)
• EPA Substance Registry System: (5R,8R,10R)-2-chloro-6-methyl-8-ergolinylmethyl p-toluenesulfonate(74627-27-3)

Safety Data

• Hazardous Substances Data: 74627-27-3(Hazardous Substances Data)

Upstream product

• 3006-19-7 9,10-dihydrolysergic acid methyl ester 
• 5878-43-3 9,10-dihydrolysergic acid 
• 110883-13-1 methyl (5R,8R,10R)-2-chloro-6-methyl-8-ergolinecarboxylate 
• 98-59-9 p-toluenesulfonyl chloride 
• 66835-16-3 ((6aR,9R,10aR)-5-Chloro-7-methyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinolin-9-yl)-methanol 

Downstream Products

• 162070-35-1 (6aR,9R,10aR)-5-Chloro-7-methyl-9-(2-phenyl-imidazol-1-ylmethyl)-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline 
• 162070-36-2 (6aR,9R,10aR)-5-Chloro-7-methyl-9-[1,2,4]triazol-1-ylmethyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline 
• 162070-34-0 (6aR,9R,10aR)-5-Chloro-9-imidazol-1-ylmethyl-7-methyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline 

Relevant articles and documents

Synthesis and structure-activity relationships of new (5R,8R,10R)-ergoline derivatives with antihypertensive or dopaminergic activity

A series of new (5R,8R,10R)-ergoline derivatives was synthesized, and their antihypertensive and dopaminergic activities were tested in conscious spontaneously hypertensive rats and in rats with unilateral 6- hydroxydopamine-induced lesions of the substantia nigra. (5R,8R,10R)-6- Alkyl-8-ergolinemethanols, prepared from the corresponding ergolinecarboxylates, were converted to the tosylates, which were treated with various five-membered heterocycles containing nitrogen atoms to afford the new ergolines. (5R,8R,10R)-8-(1,2,4-Triazol-1-ylmethyl)-6-methylergoline (4s, maleate: BAM-1110) exhibited potent dopaminergic activity, about 18- fold greater than that of bromocriptine mesylate. (5R,8R,10R)-8-(1,2,4- Triazol-1-ylmethyl)-6-propylergoline (8b, fumarate: BAM-1602) showed extremely potent dopaminergic activity, being about 220 and 1.15 times more active than bromocriptine mesylate and pergolide mesylate, respectively. Several compounds exhibited potent antihypertensive activity. Structure- activity relationships for antihypertensive and dopaminergic activities are discussed.